## Edgar Filing: Cara Therapeutics, Inc. - Form 4

	peutics, Inc.									
Form 4	017									
March 10, 2	ЛЛ		CECU			CH ANGE			APPROVAL	
. •	•••• UNITI	ED STATES		<b>ECURITIES AND EXCHANGE COMMISSION</b> Washington, D.C. 20549				N OMB Number:	3235-0287	
Check t				washington, D.C. 20347					January 31,	
if no lor subject Section Form 4 Form 5	to SIAI 16. or		OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Estimated burden ho response.	urs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Lewis Michael E			2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer			
(Lost)	(First)	(Middle)	Cara Therapeutics, Inc. [CARA]				(Check all applicable)			
(Last)	(Flist)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)				Director 10% Owner			
	A THERAPEU ELM STREET		03/08/2				XOfficer (g below) Chie	ive titleOt below) of Scientific Adv	her (specify isor	
	(Street)		4. If Amendment, Date Original			ıl	6. Individual or Joint/Group Filing(Check			
			Filed(Mo	onth/Day/Year	)			y One Reporting I		
STAMFOR	RD, CT 06902						Person	y More than One F	Reporting	
(City)	(State)	(Zip)	Tał	ole I - Non-D	erivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye		Date, if	Transactior Code	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	eport on a separate	line for each cla	ass of sec	urities benefi	icially ow	ned directly of	or indirectly.			
					inforr requi	nation cont red to respo ays a curre	spond to the coll ained in this form ond unless the fo ntly valid OMB co	m are not orm	SEC 1474 (9-02)	
				curities Acqu ls, warrants,			Beneficially Owne securities)	ed		
1. Title of Derivative		Transaction Da /onth/Day/Year		Deemed ation Date, if	4. Transa	5. Numb ctiorDerivativ		ercisable and Date	7. Title and Amount of Underlying Securities	

## Edgar Filing: Cara Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired or Dispos (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 17.41	03/08/2017		A	20,000		<u>(1)</u>	03/08/2027	Common Stock	20,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
	Director	10% Owner	Officer	Other			
Lewis Michael E C/O CARA THERAPEUTICS, INC. 107 ELM STREET, 9TH FLOOR STAMFORD, CT 06902			Chief Scientific Advisor				
Signatures							
/s/Darren DeStefano, Attorney-in-Fact	03/10/2017						
**Signature of Reporting Person	I	Date					
Fruitan attain of Deans		_					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the reporting person's Continuous Service (as defined in the 2014 Equity Incentive Plan) as of each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.